Every 8-K that Arbutus Biopharma Corporation (ABUS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ABUS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ABUS filings page.
Arbutus Biopharma Corporation (ABUS) announced plans to launch a modified “Dutch auction” tender offer to repurchase up to US$230 million of its common shares. The company expects to offer shareholders the opportunity to tender shares within a price range of US$5.00 to US$5.75 per share.
The offer is expected to commence on or about August 24, 2026 and, unless extended or terminated, expire on or about September 29, 2026. It is expected to be funded using the company’s cash on hand, including proceeds associated with a March 2026 settlement with Moderna and an initial payment received in July 2026.
Arbutus states that the offer has not yet commenced and is subject to obtaining certain exemptive relief under U.S. and Canadian securities laws, including for a proportionate tender feature and certain extension requirements. The company plans to file a Schedule TO and related offer documents when the tender offer begins.
Arbutus Biopharma reported second quarter 2026 revenue of $1.0 million, down sharply from $10.7 million a year earlier, and a net loss of $5.1 million versus net income of $2.5 million in the prior-year quarter, driven largely by the absence of one-time deferred revenue recognized in 2025.
Despite the quarterly loss, Arbutus highlighted a significantly stronger balance sheet. As of June 30, 2026, it held $92.6 million in cash, cash equivalents and marketable securities and recorded a $179.4 million receivable from its Genevant license, reflecting its share of a $950 million global settlement with Moderna, including a $178.4 million noncontingent payment received in July and a further $1.3 billion potential contingent payment tied to appellate outcomes. The company stated it expects, subject to board approval, to return up to approximately $230 million to shareholders beginning in the third quarter of 2026 through possible share repurchases. Research and development expenses fell to $2.9 million from $5.5 million due to prior restructuring, while general and administrative costs rose to $3.9 million. Arbutus also reported FDA Fast Track designation and Phase 2b trial design alignment for its HBV candidate imdusiran and disclosed new international patent enforcement lawsuits filed with Genevant against Pfizer and BioNTech relating to lipid nanoparticle technology.
Arbutus Biopharma detailed several outcomes from its mRNA patent disputes. A March 2026 settlement with Moderna generated a $950 million noncontingent lump sum to Arbutus and Genevant, of which Arbutus received about $178 million (including reimbursed litigation costs), and provides for a potential contingent payment of up to $1.3 billion. Arbutus also terminated a prior RSV-related sharing agreement with Genevant in exchange for a $1.0 million termination fee.
The board approved one-time litigation-related cash bonuses for the CEO and for the CFO, whose bonus equals 0.25% of proceeds tied to the Moderna settlement. Arbutus and Genevant filed three international patent lawsuits against Pfizer/BioNTech over lipid nanoparticle technology, seeking monetary relief and injunctions. Arbutus expects to return capital to shareholders through repurchases of up to approximately $230 million of common shares after an anticipated dividend from its approximately 16% equity stake in Genevant’s parent, though any repurchase remains subject to board approval and may not occur.
Arbutus Biopharma Corporation reported results from its 2026 Annual General and Special Meeting of Shareholders. Shareholders approved the new 2026 Omnibus Share and Incentive Plan, which authorizes issuance of an aggregate 16,300,000 common shares to support future equity-based compensation.
All director nominees were elected with strong majorities. Shareholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers and ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Arbutus Biopharma reported a dramatic turnaround in the first quarter of 2026 driven by a major litigation settlement. Total revenue surged to $179.1 million, largely from $178.7 million of license revenue from Genevant tied to the Noncontingent Settlement Payment under its settlement with Moderna. This shift turned last year’s loss into net income of $169.7 million, compared with a net loss of $24.5 million in the prior-year quarter.
Cash, cash equivalents and marketable securities were $95.2 million as of March 31, 2026, modestly higher than at year-end. Research and development expenses fell to $4.1 million, reflecting workforce reductions, discontinued in-house research and lower clinical trial costs, while restructuring costs dropped to zero. The company also highlighted that the FDA granted Fast Track designation to its HBV RNAi therapeutic imdusiran, which may facilitate development and expedite review for chronic hepatitis B.
Arbutus Biopharma reported improved 2025 results and a transformative litigation settlement. Cash, cash equivalents and marketable securities were $91.5 million as of December 31, 2025, down from $122.6 million a year earlier as the company used $39.6 million in operating activities, partly offset by option exercises.
Total 2025 revenue rose to $14.1 million from $6.2 million, driven by recognition of previously deferred Qilu partnership revenue. Operating expenses fell sharply to $52.2 million from $82.5 million due to R&D and G&A cuts and restructuring, reducing net loss to $33.5 million, or $0.17 per share, versus $69.9 million, or $0.38 per share, in 2024.
Arbutus and Genevant reached a $2.25 billion global settlement with Moderna over lipid nanoparticle technology, including a $950 million noncontingent payment due in July 2026 and a $1.3 billion contingent payment tied to a Section 1498 appellate ruling. Arbutus will receive 20% of the noncontingent payment after litigation costs and also owns about 16% of Genevant. The company is evaluating a return of capital to shareholders after receiving its portion. Clinical updates include a total of 10 Phase 2a imdusiran patients achieving functional cure in chronic hepatitis B, with most maintaining durable responses.
Arbutus Biopharma and Genevant have entered a global patent settlement with Moderna totaling up to $2.25 billion. Moderna will pay $950 million as a noncontingent lump sum in July 2026 and a further $1.3 billion only if Moderna’s appeal under U.S. Section 1498 is resolved in Arbutus/Genevant’s favor or not pursued. If the appellate court finds that Section 1498 bars only some vaccine doses, the contingent amount will be prorated, and under certain later reversals Arbutus/Genevant must repay it with interest.
The agreement ends all LNP-related litigation with Moderna and includes a fully paid-up, royalty-free, irrevocable, non-exclusive worldwide license and covenant not to sue for Moderna’s SM-102–based mRNA vaccines for infectious diseases meeting specified conditions. Under Arbutus’s license with Genevant, Arbutus is entitled to 20% of settlement proceeds after litigation costs and is evaluating a potential return of capital to shareholders in the third quarter of 2026 tied to the upfront payment.
Arbutus Biopharma reported a key court ruling in its patent case against Moderna over lipid nanoparticle technology used in the COVID‑19 vaccine mRNA‑1273. The Delaware federal court held that inter partes review estoppel and issue preclusion bar Moderna from pursuing obviousness defenses against several Arbutus patents and rejected Moderna’s derivation defense to U.S. Patent No. 9,504,651. However, the judge found that Moderna’s expert evidence on enablement creates factual disputes, so Moderna may still argue that the asserted patents are not enabled at trial. The court also excluded obviousness opinions from one Moderna expert while allowing another expert’s enablement opinions to be presented to a jury.
Arbutus Biopharma Corporation reported a key court decision in its patent lawsuit, brought with Genevant, against Moderna over lipid nanoparticle (LNP) technology used in Moderna’s COVID‑19 vaccine mRNA‑1273. A U.S. District Court in Delaware largely rejected Moderna’s argument that the case belongs in the Court of Federal Claims under a statute covering inventions used “for the Government,” limiting that defense to vaccine doses given directly to U.S. government employees.
The Court also held that Arbutus is barred by prosecution history estoppel from relying on the doctrine of equivalents for several “molar ratio” LNP patents, meaning it must prove literal infringement on those claims. At the same time, the judge found that disputes over whether Arbutus’s patents are invalid as indefinite must be decided by a jury and allowed expert testimony on that issue, while excluding several other experts on both sides.
Arbutus Biopharma Corporation reports that the Board of Appeal of the European Patent Office has revoked its European patent EP 2279254. The verbal decision followed oppositions filed by affiliates of Moderna and Merck and reverses earlier decisions that had upheld an amended version of this patent.
A written decision is expected in the coming months, after which Arbutus plans to petition the Enlarged Board of Appeal for review. The company states that the revocation is likely to affect its case against Moderna in Switzerland and one of its two cases against Moderna before the Unified Patent Court where this patent is asserted.
Arbutus notes that the decision rests on an EPO “added matter” standard that does not apply in the United States or other jurisdictions where it is pursuing patent infringement litigation. It does not expect the ruling to affect the potential outcome or timing of its ongoing cases against Moderna in the United States, Japan, Canada, its separate Unified Patent Court case that does not involve this patent, or its litigation against Pfizer and BioNTech in the United States.
Arbutus Biopharma Corporation filed a current report stating that its Chairperson, Chief Executive Officer and President, Lindsay Androski, is giving a presentation on the company’s ongoing patent litigation involving its lipid nanoparticle technology used in COVID-19 vaccines at Roivant Sciences Ltd.’s 2025 Investor Day. The related litigation slide deck is furnished as Exhibit 99.1 and incorporated by reference.
The company notes that these slides contain forward-looking statements about its plans and expected timing for the litigation. It cautions that these statements rely on assumptions and are subject to significant uncertainties, including risks associated with litigation generally, economic and market conditions, possible shifts in strategic focus, and the sufficiency of its cash resources. Arbutus refers readers to risk discussions in its annual and quarterly SEC reports and other continuous disclosure filings.
Arbutus Biopharma (ABUS) reported that it furnished a press release announcing its financial results for the third quarter ended September 30, 2025. The company also made available an updated corporate presentation.
The press release is provided as Exhibit 99.1 under Item 2.02, and the corporate presentation is filed as Exhibit 99.2 under Item 8.01. Both were dated November 13, 2025 and are incorporated by reference.
Arbutus Biopharma Corporation reported that three abstracts featuring imdusiran data and one abstract featuring AB-101 data have been accepted for poster presentations at the American Association for the Study of Liver Diseases – The Liver Meeting® 2025 in Washington, DC. The meeting is scheduled for November 7–11, 2025.
The company noted that the AB-101 abstract has been selected as a Poster of Distinction, highlighting it among the conference’s poster presentations. These details were originally shared in a press release dated October 7, 2025, which is attached as an exhibit.
Arbutus Biopharma Corporation reported that the U.S. District Court for the District of New Jersey issued a claim construction ruling in its ongoing patent lawsuit against Pfizer Inc. and BioNTech SE. The case, brought by Arbutus and its licensee Genevant Sciences, seeks damages for alleged infringement of several U.S. patents related to the manufacture and sale of Pfizer/BioNTech’s COVID-19 mRNA-based vaccines. The court’s detailed claim construction order and opinion, dated September 9, 2025, have been filed as an exhibit to this report, providing the interpretations that will guide how the patent claims are applied as the litigation continues.
Arbutus Biopharma (NASDAQ:ABUS) announced the termination of its technology transfer and license agreement with Qilu Pharmaceutical Co., Ltd. The agreement, originally established in December 2021, granted Qilu exclusive rights to develop, manufacture, and commercialize imdusiran in Greater China and Taiwan.
The mutual termination, effective June 20, 2025, involves no financial payments and results in all rights for imdusiran in Greater China and Taiwan reverting to Arbutus. This decision aligns with Qilu's pipeline reprioritization and Arbutus's strategic focus on efficient pipeline advancement.